Xcout Intel
Aspen Neuroscience
Aspen Neuroscience, Inc. is a clinical-stage private biotechnology company headquartered in San Diego, California. The company focuses on developing personalized autologous cell therapies for neurodegenerative diseases.
Subscribe to see Aspen Neuroscience’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Aspen Neuroscience at a glance
Aspen Neuroscience is a biotechnology company headquartered in United States. It has raised at least $262.5M across the 3 funding rounds on record, 2 of them with a disclosed amount. Its most recent funding round, Series C, raised $115M in November 2025. Xcout tracks 12 named people at Aspen Neuroscience, including Damien McDevitt (President and Chief Executive Officer).
Aspen Neuroscience leadership
- Damien McDevittPresident and Chief Executive Officer
- Dalen MeeterChief Financial Officer
- Kim RaineriChief Technology Officer
- Ana SousaChief Regulatory Officer
- Lisa Johnson-PrattChief Commercial Officer
- Revati ShreeniwasChief Medical Officer
6 more named people on record for Aspen Neuroscience, with roles, board committees and tenure — see the full roster →
Aspen Neuroscience funding rounds
At least $262.5M raised across the 3 rounds on record (2 with a disclosed amount). Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series C | $115M | 13 named | |
| — | $147.5M | 14 named | |
| — | Undisclosed | 13 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
Aspen Neuroscience competitors
A few of Aspen Neuroscience's closest competitors — see the full list of competitors and alternatives →
Prevail Therapeutics Inc. is a biotechnology company headquartered in New York City, New York, focused on developing gene therapies for patients with neurodegenerative diseases.
Neuron23 is a biotechnology company founded in 2018 that focuses on developing precision therapeutics for genetic diseases. Headquartered in South San Francisco, California, the company relies on a team of scientific experts and entrepreneurs.
Voyager Therapeutics, Inc. operates as a gene therapy company, concentrating its efforts on developing innovative treatments and pioneering advanced platform technologies. Its leading clinical asset, VY-AADC, is presently undergoing an open-label Phase 1 clinical trial for the management of Parkinson's disease. The company's preclinical portfolio is extensive, featuring VY-SOD102 for amyotrophic lateral sclerosis (ALS), VY-HTT01 for Huntington's disease, and VY-FXN01 for Friedreich's ataxia. Additionally, Voyager is pursuing a Tau program aimed at various tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, alongside initiatives for spinal muscular atrophy. To advance its gene therapy product pipeline, the company has forged strategic collaboration and licensing agreements with key industry players such as Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. These partnerships cover the research, development, and commercialization of adeno-associated virus-based gene therapy products. Voyager Therapeutics, Inc. was founded in 2013 and maintains its corporate headquarters in Cambridge, Massachusetts.
Neurogene Inc. is dedicated to engineering transformative genetic treatments for individuals and their families grappling with debilitating neurological conditions. Its current pipeline prominently features two key investigational therapies: NGN-401, an AAV9 gene therapy specifically targeting Rett syndrome, and NGN-101, which is being developed to address neuronal ceroid lipofuscinosis subtype 5 (Batten disease). The company's operations are based in New York, New York.
Rejuvenate Bio, Inc. is a biotechnology company founded in 2019 and headquartered in San Diego, United States, specializing in innovative gene therapy applications.
Nido Biosciences, Inc. is a clinical-stage holding and biotechnology company headquartered in Watertown, Massachusetts. The company focuses on discovering and advancing treatments for debilitating neurological diseases, including the development of targeted drugs.
Get Aspen Neuroscience's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Aspen Neuroscience in Xcout Intel
- 12 named people with titles, LinkedIn and board committees
- 3 funding rounds with the investors in each, and who they co-invest with
- 1 corporate event with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access